Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

被引：60
|
作者：
Strickler, John H. [1 ]
Hurwitz, Herbert I. [1 ]
机构：
[1] Duke Univ, Med Ctr, Div Hematol & Oncol, Durham, NC 27710 USA
来源：
ONCOLOGIST | 2012年 / 17卷 / 04期
关键词：
Bevacizumab; Colorectal cancer; Drug toxicity; Combination drug therapy; Vascular endothelial growth factor; ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; ARTERIAL THROMBOEMBOLIC EVENTS; OXALIPLATIN-BASED CHEMOTHERAPY; 2 DIFFERENT SCHEDULES; ANTI-VEGF; PLUS BEVACIZUMAB; ORAL FLUOROPYRIMIDINES; ANGIOGENESIS INHIBITOR; VENOUS THROMBOEMBOLISM;
D O I：
10.1634/theoncologist.2012-0003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Since its approval for the first-line treatment of metastatic colorectal cancer (mCRC), bevacizumab has become a standard treatment option in combination with chemotherapy for patients with mCRC. Bevacizumab has demonstrated efficacy in combination with a number of different backbone chemotherapy regimens, and its widespread use has introduced several important questions regarding the selection and optimization of bevacizumab-based treatment regimens, its use in various patient populations, and the identification of associated adverse events. This review discusses the results of several phase II and phase III clinical trials, as well as large observational studies, to address the use of bevacizumab in the treatment of patients with mCRC in the first-line setting. The Oncologist 2012;17:513-524
引用
收藏
页码：513 / 524
页数：12
相关论文
共 50 条
  • [31] Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer:The OBELIX study
    Lorenzo Antonuzzo
    Elisa Giommoni
    Davide Pastorelli
    Tiziana Latiano
    Ida Pavese
    Domenico Azzarello
    Michele Aieta
    Ilaria Pastina
    Francesca Di Fabio
    Alessandro Bertolini
    Domenico Cristiano Corsi
    Selene Mogavero
    Valentina Angelini
    Mario Pazzagli
    Francesco Di Costanzo
    [J]. World Journal of Gastroenterology, 2015, (23) : 7281 - 7288
  • [32] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    Feliu, J.
    Barriuso, J.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 104 (01) : 226 - 226
  • [33] Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy
    Kanat, Ozkan
    Ertas, Hulya
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2019, 10 (02): : 52 - 61
  • [34] Bevacizumab in combination with chemotherapy in the first-line treatment of metastatic colorectal carcinoma
    Usakova, V.
    Sevcikova, K.
    Usak, J.
    Bartosova, Z.
    Mikulova, M.
    Spanik, S.
    [J]. NEOPLASMA, 2013, 60 (01) : 83 - 91
  • [35] BEVACIZUMAB EFFECTIVENESS IN FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER, IN RELATION TO KRAS EXPRESSION AND METASTATIC SITES
    Rossi, Luigi
    Veltri, Enzo
    Zullo, Angelo
    Zoratto, Federica
    Colonna, Maria
    Del Bene, Gabriella
    Mottolese, Marcella
    Giannarelli, Diana
    Ruco, Luigi
    Romiti, Adriana
    Barucca, Viola
    Adua, Daniela
    Arcangeli, Giancarlo
    Cianni, Roberto
    Giannini, Giuseppe
    Sacchi, Marco
    Tomao, Silverio
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 104 - 104
  • [36] Effect of bevacizumab combined with first-line chemotherapy on metastatic colorectal cancer
    Xiong, Lifeng
    Lou, Yinmei
    Wang, Lin
    [J]. AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (04): : 3609 - 3617
  • [37] Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis
    Modest, Dominik Paul
    Reinacher-Schick, Anke
    Stintzing, Sebastian
    Giessen, Clemens
    Tannapfel, Andrea
    Laubender, Ruediger Paul
    Brodowicz, Thomas
    Knittelfelder, Regina
    Vrbanec, Damir
    Schmiegel, Wolff
    Heinemann, Volker
    Zielinski, Christoph C.
    [J]. ANTI-CANCER DRUGS, 2012, 23 (06) : 666 - 673
  • [38] First-line Treatment of Metastatic Breast Cancer: Focus on Bevacizumab
    Fujii, Teruhiko
    Takahashi, Hiroki
    Matsubayashi, Roka Namoto
    Inoue, Yuka
    Takenaka, Miki
    Toh, Uhi
    Kage, Masayoshi
    Yamana, Hideaki
    Shirouzu, Kazuo
    [J]. CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 583 - 593
  • [39] Use of bevacizumab as a first-line treatment for metastatic breast cancer
    Manso, L.
    Moreno, F.
    Marquez, R.
    Castelo, B.
    Arcediano, A.
    Arroyo, M.
    Ballesteros, A. I.
    Calvo, I.
    Echarri, M. J.
    Enrech, S.
    Gomez, A.
    Gonzalez del Val, R.
    Lopez-Miranda, E.
    Martin-Angulo, M.
    Martinez-Janez, N.
    Olier, C.
    Zamora, P.
    [J]. CURRENT ONCOLOGY, 2015, 22 (02) : E51 - E60
  • [40] Cetuximab for the first-line treatment of metastatic colorectal cancer
    Meads, C.
    Round, J.
    Tubeuf, S.
    Moore, D.
    Pennant, M.
    Baylis, S.
    [J]. HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 1 - 8
12345